All In Biotech

Drug Trial Radar · NCT07470762

Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal Hemoglobinuria

A Phase IB/II,Open Label Study to Assess Efficacy, and Safety, of HS-10542 in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Feb 14, 2026

Primary completion

May 30, 2027

Study completion Jul 31, 2029

Sponsor

Sponsor type
Industry
First posted
Mar 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a phase 1b/2,open label, multi-center study to assess efficacy and safety of HS-10542 in adulte patients with paroxysmal nocturnal hemoglobinuria (PNH) with signs of active hemolysis.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • HS-10542Drug

    HS-10542 low dose,QD

  • HS-10542Drug

    HS-10542 high dose, QD

  • HS-10542Drug

    Orally QD ,The recommended dose from Ph1b

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Incidence and severity of adverse eventsTime frame: 12 weeks
  2. Phase 2: In the absence of red blood cell infusion the proportion of subjects with at least 3 times of ≥120 g/L of hemoglobin level measured 4 times between weeks 18 and 24Time frame: From the 18th to the 24th week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital,Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.